Gainers

• Arcellx (NASDAQ:ACLX) shares rose 77.6% to $113.83 during Monday's regular session. The market value of their outstanding shares is at $3.7 billion.
• Vanda Pharmaceuticals (NASDAQ:VNDA) stock increased by 40.41% to $8.09. The market value of their outstanding shares is at $340.4 million.
• Genprex (NASDAQ:GNPX) stock moved upwards by 22.75% to $2.19. The company's market cap stands at $4.0 million.
• Jyong Biotech (NASDAQ:MENS) stock increased by 22.69% to $2.47. The company's market cap stands at $152.8 million.
• Enhabit (NYSE:EHAB) shares moved upwards by 22.58% to $13.6. The market value of their outstanding shares is at $561.2 million.
• Fortress Biotech (NASDAQ:FBIOP) shares increased by 20.52% to $13.26. The market value of their outstanding shares is at $37.6 million.

Losers

• Gossamer Bio (NASDAQ:GOSS) stock declined by 83.5% to $0.35 during Monday's regular session. The company's market cap stands at $493.0 million.
• 20/20 Biolabs (NASDAQ:AIDX) shares fell 28.99% to $10.49. The company's market cap stands at $152.9 million.
• iSpecimen (NASDAQ:ISPC) stock declined by 17.38% to $0.23. The market value of their outstanding shares is at $2.7 million.
• Novo Nordisk (NYSE:NVO) shares decreased by 15.18% to $40.23. The market value of their outstanding shares is at $210.8 billion.
• Neuraxis (AMEX:NRXS) shares decreased by 14.83% to $4.71. The company's market cap stands at $58.9 million.
• GRAIL (NASDAQ:GRAL) stock fell 14.03% to $43.17. The company's market cap stands at $1.9 billion. As per the news, the Q4 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.